{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:20Z","timestamp":1790803700838,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014173","name":"Shenzhen Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.autrev.2023.103335","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:32:48Z","timestamp":1683549168000},"page":"103335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"Hongli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2023.103335_bb0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study[J]","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis[J]","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.autrev.2023.103335_bb0015","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients[J]","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0020","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and Meta-analysis[J]","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis[J]","volume":"40","author":"Long","year":"2019","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.autrev.2023.103335_bb0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fmed.2019.00326","article-title":"Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment[J]","volume":"6","author":"Hervier","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MCP.0000000000000698","article-title":"Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases[J]","volume":"26","author":"Yanagihara","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40674-018-0110-6","article-title":"Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications[J]","volume":"5","author":"Shappley","year":"2019","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.autrev.2023.103335_bb0045","first-page":"7","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses[J]","author":"Wells","year":"2014","journal-title":"Ottawa Health Res Inst Web"},{"issue":"11","key":"10.1016\/j.autrev.2023.103335_bb0050","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jclinepi.2013.06.017","article-title":"Assessing the applicability of findings in systematic reviews of complex interventions can enhance the utility of reviews for decision making[J]","volume":"66","author":"Burford","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"7129","key":"10.1016\/j.autrev.2023.103335_bb0055","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased[J]","volume":"316","author":"Irwig","year":"1998","journal-title":"Bmj"},{"issue":"11","key":"10.1016\/j.autrev.2023.103335_bb0060","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis[J]","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7414","key":"10.1016\/j.autrev.2023.103335_bb0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses[J]","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.autrev.2023.103335_bb0070","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study[J]","volume":"26","author":"Ye","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3760\/cma.j.issn.0366-6999.2010.05.002","article-title":"Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study[J]","volume":"123","author":"Ji","year":"2010","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"10.1016\/j.autrev.2023.103335_bb0080","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3899\/jrheum.101002","article-title":"Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan[J]","volume":"38","author":"Yamasaki","year":"2011","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103335_bb0085","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-011-1840-0","article-title":"Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases[J]","volume":"30","author":"Yu","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/s10165-012-0673-2","article-title":"Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease[J]","volume":"23","author":"Woo","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103335_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/RHU.0000000000000365","article-title":"Clinical and prognostic factors associated with survival in Mexican patients with idiopathic inflammatory myopathies[J]","volume":"22","author":"Galindo-Feria","year":"2016","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/14397595.2015.1054081","article-title":"Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors[J]","volume":"26","author":"Ishizuka","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0105","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease[J]","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.autrev.2023.103335_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies[J]","volume":"11","author":"Sato","year":"2016","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.autrev.2023.103335_bb0115","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis[J]","volume":"56","author":"Abe","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical Spectrum in north American patients with dermatomyositis[J]","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190411","article-title":"Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: a retrospective observational study[J]","volume":"13","author":"Ha","year":"2018","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.autrev.2023.103335_bb0130","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2019.34.e55","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a Nationwide population-based study[J]","volume":"34","author":"Cho","year":"2019","journal-title":"J Korean Med Sci"},{"issue":"8","key":"10.1016\/j.autrev.2023.103335_bb0135","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/1756-185X.13559","article-title":"Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry[J]","volume":"22","author":"Nu\u00f1o-Nu\u00f1o","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0140","first-page":"586","article-title":"Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis\/dermatomyositis[J]","volume":"59","author":"Watanabe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0145","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10067-019-04910-w","article-title":"Mortality of Chinese patients with polymyositis and dermatomyositis[J]","volume":"39","author":"Yang","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103335_bb0150","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.rmed.2007.01.023","article-title":"Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases[J]","volume":"101","author":"Ideura","year":"2007","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/sarh.2002.50012","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment[J]","volume":"32","author":"Schnabel","year":"2003","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis[J]","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.autrev.2023.103335_bb0165","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin a, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis[J]","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis[J]","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"issue":"8","key":"10.1016\/j.autrev.2023.103335_bb0175","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series[J]","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2023.103335_bb0180","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis[J]","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103335_bb0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome[J]","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2023.103335_bb0190","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12026-013-8408-9","article-title":"Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature[J]","volume":"56","author":"Nalotto","year":"2013","journal-title":"Immunol Res"},{"issue":"9","key":"10.1016\/j.autrev.2023.103335_bb0195","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population[J]","volume":"53","author":"Unger","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103335_bb0200","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis[J]","volume":"176","author":"Matsushita","year":"2017","journal-title":"Brit J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103335_bb0205","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis[J]","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (United Kingdom)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103335_bb0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1756-185X.13414","article-title":"Efficacy and safety of oral high-trough level tacrolimus in acute\/subacute interstitial pneumonia with dermatomyositis[J]","volume":"22","author":"Suzuka","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0215","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103335_bb0220","doi-asserted-by":"crossref","first-page":"E227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis[J]","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology (United Kingdom)"},{"issue":"6","key":"10.1016\/j.autrev.2023.103335_bb0225","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy[J]","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103335_bb0230","first-page":"7","article-title":"Antisynthetase syndrome-associated interstitial lung disease: monitoring of immunosuppressive treatment effects by chest computed tomography[J]","author":"Korsten","year":"2020","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103335_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089610","article-title":"Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute\/subacufte interstitial pneumonia in dermatomyositis treated by cyclosporine A\/glucocorticosteroid combination therapy: A case control study[J]","volume":"9","author":"Isoda","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","article-title":"Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study[J]","volume":"8","author":"Vuillard","year":"2018","journal-title":"Ann Intensive Care"},{"issue":"8","key":"10.1016\/j.autrev.2023.103335_bb0245","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3899\/jrheum.180825","article-title":"Clinical significance of serum Chitotriosidase level in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease[J]","volume":"46","author":"Fujisawa","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103335_bb0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fmed.2019.00239","article-title":"Efficiency of therapeutic plasma-exchange in acute interstitial lung disease, associated with polymyositis\/dermatomyositis resistant to glucocorticoids and immunosuppressive drugs: a retrospective study[J]","volume":"6","author":"Ning","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2023.103335_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD[J]","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.autrev.2023.103335_bb0260","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment[J]","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14397595.2020.1740400","article-title":"Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age[J]","volume":"31","author":"Yamaguchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103335_bb0270","first-page":"1","article-title":"Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis[J]","author":"Komai","year":"2021","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103335_bb0275","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin a and 2-hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis[J]","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103335_bb0280","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00296-013-2735-y","article-title":"Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis[J]","volume":"33","author":"Ishigaki","year":"2013","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2023.103335_bb0285","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2013.844390","article-title":"Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease[J]","volume":"24","author":"Nara","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103335_bb0290","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10067-012-2142-x","article-title":"Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis[J]","volume":"32","author":"Muro","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103335_bb0295","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease[J]","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"issue":"10","key":"10.1016\/j.autrev.2023.103335_bb0300","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study[J]","volume":"26","author":"Ye","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020[J]","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2023.103335_bb0310","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2023.103335_bb0315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-5945-14-9","article-title":"HLA class II alleles may influence susceptibility to adult dermatomyositis and polymyositis in a Han Chinese population[J]","volume":"14","author":"Gao","year":"2014","journal-title":"BMC Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103335_bb0320","first-page":"1768","article-title":"Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy[J]","volume":"31","author":"Furuya","year":"2004","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103335_bb0325","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/kes167","article-title":"Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort[J]","volume":"51","author":"Chua","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103335_bb0330","article-title":"Management of interstitial lung disease associated with connective tissue disease[J]","volume":"352","author":"Mathai","year":"2016","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0335","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of Myositis-Related Interstitial Lung Disease[J]","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.autrev.2023.103335_bb0340","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of Antisynthetase syndrome[J]","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103335_bb0345","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.chest.2020.01.033","article-title":"Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease[J]","volume":"158","author":"Jablonski","year":"2020","journal-title":"Chest"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:30:00Z","timestamp":1761600600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1568997223000691"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103335","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103335"}}